Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.

The phospholipase A(2) receptor (PLA(2)R) is the major target antigen in idiopathic membranous nephropathy. The technique for measuring antibodies against PLA(2)R and the relationship between antibody titer and clinical characteristics are not well established. Here, we measured anti-PLA(2)R (aPLA(2)R) antibody titer and subclass in a well defined cohort of 117 Caucasian patients with idiopathic membranous nephropathy and nephrotic-range proteinuria using both indirect immunofluorescence testing (IIFT) and ELISA. We assessed agreement between tests and correlated antibody titer with clinical baseline parameters and outcome. In this cohort, aPLA(2)R antibodies were positive in 74% and 72% of patients using IIFT and ELISA, respectively. Concordance between both tests was excellent (94% agreement, κ=0.85). Among 82 aPLA(2)R-positive patients, antibody titer significantly correlated with baseline proteinuria (P=0.02). Spontaneous remissions occurred significantly less frequently among patients with high antibody titers (38% versus 4% in the lowest and highest tertiles, respectively; P<0.01). IgG4 was the dominant subclass in the majority of patients. Titers of IgG4, but not IgG1 or IgG3, significantly correlated with the occurrence of spontaneous remission (P=0.03). In summary, these data show high agreement between IIFT and ELISA assessments of aPLA(2)R antibody titer and highlight the pathogenetic role of these antibodies, especially the IgG4 subclass, given the observed relationships between aPLA(2)R titer, baseline proteinuria, and outcome.

[1]  J. Wetzels,et al.  anti-Pla 2 r antibodies in membranous nephropathy: ready for routine clinical practice? , 2012 .

[2]  J. Wetzels,et al.  Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[3]  M. Prunotto,et al.  Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. , 2011, Journal of proteomics.

[4]  David M. Beck,et al.  Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[5]  U. Panzer,et al.  An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  D. Salant,et al.  Anti-phospholipase A2 receptor antibody in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[7]  David M. Beck,et al.  Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[8]  L. Kiemeney,et al.  Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. , 2011, The New England journal of medicine.

[9]  H. Debiec,et al.  PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. , 2011, The New England journal of medicine.

[10]  M. Prunotto,et al.  Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. , 2010, Journal of the American Society of Nephrology : JASN.

[11]  David M. Beck,et al.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.

[12]  J. Wetzels,et al.  Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  D. Cattran Management of membranous nephropathy: when and what for treatment. , 2005, Journal of the American Society of Nephrology : JASN.

[14]  J. Haymann,et al.  Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. , 2002, The New England journal of medicine.

[15]  J. Groothoff,et al.  Clearance ratios of amylase isoenzymes and IgG subclasses: do they reflect glomerular charge selectivity? , 1997, Nephron.

[16]  G. Mohácsi,et al.  [Secondary membranous glomerulonephritis]. , 1991, Orvosi hetilap.

[17]  J. Wetzels,et al.  Anti-PLA₂R antibodies in membranous nephropathy: ready for routine clinical practice? , 2012, The Netherlands journal of medicine.

[18]  G. Remuzzi,et al.  Early-childhood membranous nephropathy due to cationic bovine serum albumin. , 2011, The New England journal of medicine.